Northern Trust Corp Purchases 96,381 Shares of Liquidia Co. (NASDAQ:LQDA)

Northern Trust Corp lifted its position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 19.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 589,921 shares of the company's stock after buying an additional 96,381 shares during the period. Northern Trust Corp owned about 0.70% of Liquidia worth $6,937,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of LQDA. Vanguard Group Inc. lifted its stake in shares of Liquidia by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company's stock valued at $41,834,000 after acquiring an additional 115,367 shares during the last quarter. LM Advisors LLC purchased a new position in Liquidia in the 4th quarter worth approximately $25,948,000. Geode Capital Management LLC lifted its position in Liquidia by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock valued at $15,753,000 after purchasing an additional 101,597 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Liquidia by 2,675.0% during the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock valued at $8,234,000 after purchasing an additional 674,940 shares during the period. Finally, Eversept Partners LP grew its holdings in shares of Liquidia by 314.1% in the fourth quarter. Eversept Partners LP now owns 571,305 shares of the company's stock worth $6,719,000 after purchasing an additional 433,356 shares during the last quarter. Institutional investors own 64.54% of the company's stock.

Wall Street Analyst Weigh In

LQDA has been the subject of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a report on Monday, May 12th. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a research note on Monday, May 5th. HC Wainwright reissued a "buy" rating and set a $29.00 price objective on shares of Liquidia in a research report on Monday, May 12th. Raymond James upped their price objective on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Finally, Oppenheimer lowered shares of Liquidia from a "market perform" rating to an "underperform" rating and set a $13.00 target price on the stock. in a research note on Monday. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $25.56.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $17.03 on Tuesday. Liquidia Co. has a 1-year low of $8.26 and a 1-year high of $19.41. The business's 50 day moving average is $14.61 and its two-hundred day moving average is $13.46. The stock has a market capitalization of $1.46 billion, a P/E ratio of -10.45 and a beta of 0.24.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The firm had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, equities research analysts anticipate that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 5,964 shares of the business's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $80,931.48. Following the sale, the general counsel now owns 570,301 shares in the company, valued at approximately $7,738,984.57. The trade was a 1.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 2,450 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $13.67, for a total transaction of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares of the company's stock, valued at $3,597,287.84. This represents a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,138 shares of company stock valued at $450,233. Company insiders own 26.50% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.